free性video西欧极品,伊人依成久久人综合网,中文字幕人妻一区二区三区熟女,男女高潮激烈无遮挡免费观软件 ,成人3d动漫一区二区三区

  • DemeRx Receives MHRA Approval for DMX-1002 Study for Opioid Use Disorder americanpharmaceuticalreview
    March 17, 2021
    DemeRx IB, an atai Life Sciences (atai) platform company focused on developing ibogaine for the treatment of opioid use disorder (OUD), announced the company has approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to ...
  • MHRA green light for DemeRx’s opioid use disorder trial pharmatimes
    March 11, 2021
    The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the launch of a Phase I/IIa trial of DemeRx and atai Life Sciences’ ibogaine HCl (DMX-1002) for the treatment of opioid use disorder (OUD).
PharmaSources Customer Service